Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function
Cardiovascular Magnetic Resonance Evaluation of the Effects of Niaspan on Regression of Atherosclerosis and Restoration of Endothelial Function
Sponsor: Merck KGaA, Darmstadt, Germany
A NA clinical study on Atherosclerosis, this trial is ongoing. The trial is conducted by Merck KGaA, Darmstadt, Germany and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Jan 2019 — Jan 2021 [monthly]
Unknown Status NA
-
Jun 2018 — Jan 2019 [monthly]
Unknown Status NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status NA
First recorded
Sep 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
- University of Oxford
For direct contact, visit the study record on ClinicalTrials.gov .